Entero Therapeutics raises $3 million in private placement

Entero Therapeutics, Inc. (NASDAQ: ENTO) announced it entered into definitive agreements with institutional investors for a $3 million private placement of pre-funded and common warrants.

The offering consists of 4,878,841 pre-funded warrants and 9,757,682 common warrants to purchase one share of common stock per warrant. The combined purchase price for one pre-funded warrant and two common warrants is $0.6149.

The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 and may be exercised at any time until exercised in full. The common warrants have an initial exercise price of $0.3649 per share and expire 60 months after the effective date of the resale registration statement or when shares can be resold without restriction under Rule 144.

The company will receive approximately $1 million at closing and $2 million when the resale registration statement becomes effective. The transaction is expected to close on or about August 11, 2025, subject to customary closing conditions.

Entero Therapeutics plans to use the net proceeds for general corporate purposes and working capital. The securities are being sold in a private placement to accredited investors and have not been registered under the Securities Act of 1933.

The clinical-stage biopharmaceutical company develops targeted, non-systemic therapies for gastrointestinal diseases. Its programs include latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for cystic fibrosis and chronic pancreatitis patients.

Sichenzia Ross Ference Carmel LLP serves as counsel to the company, while Kaufman & Canoles, P.C. represents the investors.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Baiya International Group (BIYA) files $200M mixed shelf
• Aveanna Healthcare prices secondary offering at $11.75 per share